Drug policy impacts regional trends of ezetimibe use

Drug policy impacts regional trends of ezetimibe use

(HealthDay)—Within Canada, regional variation has been noted in ezetimibe use, which is associated with the restrictiveness of publicly-funded drug formularies, according to a study published online June 3 in Circulation: Cardiovascular Quality and Outcomes.

Lingyun Lu, Pharm.D., from the Western University of Health Sciences in Pomona, Calif., and colleagues conducted a population-level cohort study to examine ezetimibe use in four provinces in Canada. The provinces had a gradient in the restrictiveness of ezetimibe in publicly-funded formularies (most to least restrictive: British Columbia, Alberta, Quebec, and Ontario). Use was examined using IMS Health Canada's data from June 2003 to December 2012.

The researchers observed in ezetimibe use patterns. The lowest monthly increasing rate was seen in British Columbia (most restrictive), which increased from $261 (Canadian dollars) to $21,926 from June 2003 to December 2012 ($190/100,000 population/month). In contrast, the least restrictive Ontario had the most rapid monthly increase, from $223 to $74,030 ($647/100,000 population/month). Quebec and Alberta had intermediate increases, from $130 to $59,690 ($522/100,000 population/month) and from $356 to $37,604 ($327/100,000 population/month), respectively.

"Ezetimibe use remains common, increasing during the past decade," the authors write. "The gradient in use was related to variability in restrictiveness of the provincial formularies, illustrating the potential of a policy response gradient that may be used to more effectively manage medication use."

Several authors disclosed financial ties to the pharmaceutical, medical device, and insurance industries.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Evolocumab superior to ezetimibe in lowering LDL cholesterol

date Mar 31, 2014

Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable ...

Recommended for you

Race influences warfarin dose, study says

date 2 hours ago

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), propose ...

Even moderate BMI reduction could ease A-fib burden

date 5 hours ago

(HealthDay)—Incremental increases in body mass index (BMI) are associated with excess risk of incident, postoperative, and post-ablation atrial fibrillation (AF), according to a review published online ...

Personalized saline may provide solution to heart death

date 7 hours ago

Saline solution is a staple of every hospital. No matter the ailment, doctors have known for more than a century that saline is key to keeping patients hydrated and maintaining their blood pressure levels. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.